The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy

Testing for DNA of 13 high-risk HPV types with the Hybrid Capture 2 (HC2) test has consistently been shown to perform better in triage of women with cervical cytology results showing atypical squamous cells of undetermined significance (ASC-US) but often not in triage of low-grade squamous intraepit...

Full description

Saved in:
Bibliographic Details
Main Authors: Arbyn, Marc (Author) , Roelens, Jolien (Author) , Cuschieri, Kate (Author) , Cuzick, Jack (Author) , Szarewski, Ann (Author) , Ratnam, Sam (Author) , Reuschenbach, Miriam (Author) , Belinson, Suzanne (Author) , Belinson, Jerome L. (Author) , Monsonego, Joseph (Author)
Format: Article (Journal)
Language:English
Published: 2013
In: International journal of cancer
Year: 2012, Volume: 132, Issue: 1, Pages: 101-108
ISSN:1097-0215
DOI:https://doi.org/10.1002/ijc.27636
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1002/ijc.27636
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.27636
Get full text
Author Notes:Marc Arbyn, Jolien Roelens, Kate Cuschieri, Jack Cuzick, Ann Szarewski, Sam Ratnam, Miriam Reuschenbach, Suzanne Belinson, Jerome L. Belinson and Joseph Monsonego
Description
Summary:Testing for DNA of 13 high-risk HPV types with the Hybrid Capture 2 (HC2) test has consistently been shown to perform better in triage of women with cervical cytology results showing atypical squamous cells of undetermined significance (ASC-US) but often not in triage of low-grade squamous intraepithelial lesions (LSIL) detected in cervical cancer screening. In a meta-analysis, we compared the accuracy of the APTIMA HPV test, which identifies RNA of 14 high-risk HPV types, to HC2 for the triage of women with ASC-US or LSIL. Literature search-targeted studies where the accuracy of APTIMA HPV and HC2 for detection of underlying CIN2/3+ was assessed concomitantly including verification of all cases of ASC-US and LSIL. HSROC (Hierarchical Summary ROC) curve regression was used to compute the pooled absolute and relative sensitivity and specificity. Eight studies, comprising 1,839 ASC-US and 1,887 LSIL cases, were retrieved. The pooled sensitivity and specificity of APTIMA to triage ASC-US to detect underlying CIN3 or worse was 96.2% (95% CI = 91.7-98.3%) and 54.9% (95% CI = 43.5-65.9%), respectively. APTIMA and HC2 showed similar pooled sensitivity; however, the specificity of the former was significantly higher (ratio: 1.19; 95% CI = 1.08-1.31 for CIN2+). The pooled sensitivity and specificity of APTIMA to triage LSIL were 96.7% (95% CI = 91.4-98.9%) and 38.7% (95% CI = 30.5-47.6%) for CIN3+. APTIMA was as sensitive as HC2 but more specific (ratio: 1.35; 95% CI = 1.11-1.66). Results were similar for detection of CIN2 or worse. In both triage of ASC-US and LSIL, APTIMA is as sensitive but more specific than HC2 for detecting cervical precancer.
Item Description:Gesehen am 07.12.2020
First published: 18 May 2012
Physical Description:Online Resource
ISSN:1097-0215
DOI:https://doi.org/10.1002/ijc.27636